ArticleChemistry & biodiversity2026
First GC/MS Profiling and Cytotoxic Evaluation of Physalis acutifolia (Solanaceae) Essential Oils: Insights From Molecular Docking and ADME Predictions.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Solanaceae family, particularly the genus Physalis, is a rich source of anticancer bioactive compounds. This study first reports the chemical composition of essential oils (EOs) obtained from fruits (FO), leaves (LO), and a leaf-fruit mixture (LFO) of Physalis acutifolia using gas chromatography-mass spectrometry. Major components include hexadecanoic acid (36.51% in LO), phytol (32.54% in LFO), and heptacosane (31.37% in FO). Cytotoxic activity was assessed against four human cancer cell lines: A375 (malignant melanoma), T98G (glioblastoma multiforme), MDA-MB-231 (breast adenocarcinoma), and HCT116 (colon carcinoma). LO exhibited potent antiproliferative effects on A375 (IC50 = 9.06 µg/mL). Molecular docking simulations suggest that hexadecanoic acid may activate peroxisome proliferator-activated receptor alpha (PPARα), while homosalate shows a high-affinity binding to platelet-derived growth factor receptor alpha (PDGFRA). Absorption, distribution, metabolism, and excretion (ADME) predictions indicate drug-like properties for ar-turmerol. These findings highlight the anticancer potential of P. acutifolia EOs as candidates for future pharmaceutical examination.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.